Filing Details

Accession Number:
0001567619-21-001340
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-21 16:41:11
Reporting Period:
2021-01-19
Accepted Time:
2021-01-21 16:41:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787306 Arcutis Biotherapeutics Inc. ARQT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559583 W John Smither C/O Arcutis Biotherapeutics, Inc.
3027 Townsgate Road, Suite 300
Westlake Village CA 91361
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-19 500 $1.68 25,698 No 4 M Direct
Common Stock Disposition 2021-01-19 500 $30.00 25,198 No 4 S Direct
Common Stock Disposition 2021-01-19 1,250 $30.00 93,715 No 4 S Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-01-19 500 $0.00 500 $1.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
47,482 2029-05-14 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
  3. The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  4. The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.